Dr. Kelley is the 2017 recipient of the Bantz Petronio Translating Research Into Practice Award
Since joining the Department of Pediatrics at the IU School of Medicine in 1993, Dr, Kelley’s work has focused on translational research in DNA damage and repair, specifically, to determine how those activities can be exploited therapeutically to treat cancers and protect normal cells from DNA damage.
He has focused specifically on the enzyme called APE1 as a therapeutic target in cancers and other diseases. Dr. Kelley discovered and has been developing a specific inhibitor of APE1 which he is now translating to clinical trials. This work has also led to the creation of a biotechnology company called Apexian Pharmaceuticals, of which Dr. Kelley is the Chief Scientific Founder and Officer.
The first drug developed has recently been approved by the FDA for Phase 1 clinical trials in cancer patients scheduled to begin in 2017. The drug has potential uses in a number of cancers including ovarian, colon, bladder, pancreatic, leukemia, and other adult and pediatric cancers.
He is also exploring the use of the target APE1 and the drug to prevent a major side-effect of cancer treatments called chemotherapy-induced peripheral neuropathy (CIPN).
Dr. Kelley is committed to fast-tracking collaboration and translational research efforts in order to find more effective cancer treatments. He also mentors and encourages students, post-doctorates, fellows and junior faculty in translating their research into practice to expand the number of discoveries that help solve problems and make life better.Professor Kelley's application of a business model to support research planning and implementation is another example of how IUPUI's faculty members are TRANSLATING their RESEARCH INTO PRACTICE.
Selected Publications in IUPUI ScholarWorks
With over 75 scholarly articles contributed to IUPUI's free, open access repository, Dr. Kelley has made research knowledge about the role of the DNA repair enzyme APE1/Ref-1 in cancer therapy available available to researchers, students and readers around the world.
Shah, F., Goossens, E., Atallah, N. M., Grimard, M., Kelley, M. R., & Fishel, M. L. (2017). APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma - characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing. Molecular Oncology. Available from: http://hdl.handle.net/1805/14364
Shah, F., Logsdon, D., Messmann, R. A., Fehrenbacher, J. C., Fishel, M. L., & Kelley, M. R. (2017). Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. Npj Precision Oncology, 1(1), 19. Available from: http://hdl.handle.net/1805/14363
Ding, J., Fishel, M. L., Reed, A. M., McAdams, E., Czader, M., Cardoso, A. A., & Kelley, M. R. (2017). Ref-1/APE1 as Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia. Molecular Cancer Therapeutics, molcanther.0099.2017. Available from: http://hdl.handle.net/1805/14366
Kelley, M. R., & Fehrenbacher, J. C. (2017). Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage. Neural Regeneration Research, 12(1), 72–74. Available from: http://hdl.handle.net/1805/13725
Logsdon, D. P., Grimard, M., Luo, M., Shahda, S., Jiang, Y., Tong, Y., … Fishel, M. L. (2016). Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 15(11), 2722–2732. Available from: http://hdl.handle.net/1805/14361
Georgiadis, M. M., Chen, Q., Meng, J., Guo, C., Wireman, R., Reed, A., … Kelley, M. R. (2016). Small molecule activation of apurinic/apyrimidinic endonuclease 1 reduces DNA damage induced by cisplatin in cultured sensory neurons. DNA Repair, 41(Supplement C), 32–41. Available from: http://hdl.handle.net/1805/13825
Kelley, M. R., Wikel, J. H., Guo, C., Pollok, K. E., Bailey, B. J., Wireman, R., … Vasko, M. R. (2016). Identification of new chemical entities targeting APE1 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). Journal of Pharmacology and Experimental Therapeutics, jpet.116.235283. Available from: http://hdl.handle.net/1805/14360
Li, Y., Liu, X., Zhou, T., Kelley, M. R., Edwards, P., Gao, H., & Qiao, X. (2014). Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization. Redox Biology, 2, 485-494. Available from: http://hdl.handle.net/1805/4698
Kelley, M. R., Georgiadis, M. M., & Fishel, M. L. (2012). APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Current Molecular Pharmacology, 5(1), 36. Available from: http://hdl.handle.net/1805/4688
Kelley, M. R. (2011). DNA repair inhibitors: Where do we go from here?. DNA Repair, 10(11), 1183. Available from: http://hdl.handle.net/1805/4687
Find more free articles by Mark R. Kelley in IUPUI ScholarWorks.